Executive Summary / Key Takeaways
-
The Intelligent Diagnostics flywheel is accelerating: Tempus AI has built a unique two-sided platform where its Diagnostics segment (NGS testing) feeds proprietary data into its Data & Applications segment (AI licensing), creating network effects that competitors cannot replicate. This drove 83% revenue growth in 2025 and positions the company to capture a share of the $200 billion precision oncology market.
-
Margin inflection is real and sustainable: Achieving positive adjusted EBITDA in Q3 2025 after a decade of investment reflects operating leverage from a 111% surge in Diagnostics revenue and 126% net revenue retention in the Data business. With 2026 guidance calling for $65 million in adjusted EBITDA on $1.59 billion revenue, the company is demonstrating that its heavy R&D spending is translating into profitable scale.
-
AI reimbursement represents a binary catalyst: The U.S. healthcare system's current structure for AI algorithm reimbursement is a challenge that management believes will change. With FDA-approved algorithms already reimbursed at ~$120 per test and Tempus sitting on over 450 petabytes of training data, successful reimbursement could unlock high-margin revenue that isn't factored into current guidance.
-
Competitive moats are widening: While competitors like Guardant Health (GH) and Natera (NTRA) excel in individual tests, Tempus's integrated platform—spanning oncology, hereditary testing, digital pathology, and clinical trial matching—creates switching costs evident in its 126% net revenue retention and >$1.1 billion total contract value.
-
The critical variable is litigation resolution: Patent infringement lawsuits from Guardant Health represent an immediate threat. A favorable outcome would remove an overhang and potentially accelerate liquid biopsy market share gains, while an adverse ruling could constrain Tempus's MRD and xF assay growth, impacting the $500+ ASP upside management has guided to.
Setting the Scene: The Operating System for Precision Medicine
Tempus AI, founded in August 2015 as Bioin, LLC by serial entrepreneur Eric Lefkofsky and headquartered in Chicago, Illinois, is not a traditional diagnostics company. While most competitors sell individual tests, Tempus has spent a decade building an "Intelligent Diagnostics" platform—a technology infrastructure that integrates next-generation sequencing (NGS) testing with artificial intelligence, clinical data, and a proprietary distribution network. This transforms Tempus from a lab provider into a data-driven healthcare technology company with network effects that strengthen with every test performed.
The company operates in a healthcare industry undergoing a fundamental shift. Precision oncology is projected to grow at an 8-9% CAGR to over $200 billion by 2030, but the real acceleration is coming from AI adoption. The AI medical imaging market alone is expected to hit $20 billion by 2033, growing at 34.7% annually. More importantly, pharmaceutical companies are increasingly leveraging real-world data to accelerate drug development, with R&D budgets growing 10% annually despite broader biotech funding constraints. Tempus sits at the intersection of these trends, positioned to capture value from both diagnostics and data monetization.
In the value chain, Tempus connects three critical stakeholders: healthcare providers (over 5,500 hospitals and 8,500 ordering oncologists), pharmaceutical companies (through its Data & Applications segment), and patients. Unlike pure-play diagnostics competitors such as Guardant Health or Natera, which focus solely on test volumes, Tempus uses each diagnostic test to enrich its multimodal data library. This creates a feedback loop: more tests generate more data, which improves AI algorithms, which makes tests more accurate and valuable, which drives more test adoption. Competitors can replicate individual components, but they cannot easily reproduce a decade of integrated clinical and molecular data relationships.
Technology, Products, and Strategic Differentiation: The Data Moat in Action
Tempus's core technology advantage lies in its ability to contextualize diagnostics by marrying clinical and molecular data. The Diagnostics product line includes five key assays—xT (solid tumor), xR (RNA), xF (liquid biopsy), xH (hereditary), and xE (expanded)—but the real differentiation is that these tests are connected to clinical data, making them "self-learning" and more accurate with each new test. This drives superior clinical performance and creates a barrier to entry that pure technology companies cannot match.
The Data & Applications segment monetizes this proprietary data through four products: Insights (data licensing), Trials (clinical trial matching), Next (AI-powered care gap minimization), and Algos (purely algorithmic diagnostic tests). The segment generated $316 million in 2025 revenue (+31%) with 126% net revenue retention, indicating that customers derive increasing value over time. This demonstrates that Tempus's data is a high-margin, recurring revenue asset that becomes more valuable as the dataset grows.
The April 2025 agreement with AstraZeneca (AZN) and Pathos to build the world's largest foundation model in oncology exemplifies this moat. The three-year, $200 million deal brings Tempus's total contract value to over $1.1 billion and is non-exclusive, allowing Tempus to build similar models with other partners. The first version is expected in Q1 2026. This validates that Tempus's 450 petabytes of connected multimodal data is a strategic asset, while the non-exclusive structure preserves optionality for future partnerships. The compute costs are largely covered by partners, demonstrating that Tempus can leverage its data without bearing the full capital burden.
Recent acquisitions strengthen the platform's comprehensiveness. The $692 million Ambry Genetics deal (February 2025) added hereditary testing capabilities and expanded into pediatrics, rare disease, and cardiology. The $101 million Paige.AI acquisition (August 2025) brought digital pathology capabilities, including Paige Predict, which can predict mutations from H&E slides even when NGS fails. The $17 million Deep 6 AI acquisition (March 2025) enhanced clinical trial connectivity. These deals transform Tempus from an oncology-focused player into a comprehensive precision medicine platform, increasing its addressable market and cross-selling opportunities.
Financial Performance & Segment Dynamics: Evidence of Operating Leverage
Tempus's 2025 financial results provide evidence that its strategy is working. Total revenue reached $1.27 billion, an 83% increase year-over-year, with approximately 30% organic growth excluding the Ambry acquisition. Core business revenue grew over 33%, accelerating throughout the year. This demonstrates that the underlying business is gaining momentum independent of M&A.
The Diagnostics segment's performance is particularly instructive. Revenue surged 111% to $955 million, driven by both volume and pricing power. Oncology testing volume grew 29% in Q4 2025, accelerating from 20% in Q1, while hereditary testing volume jumped 23% in Q4. Average selling prices for oncology NGS tests increased to approximately $1,600 in 2025 from $1,510 in 2024, with Q4 ASPs reaching $1,640. Management anticipates over $500 of additional ASP upside from migrating xT CDx to the FDA-approved version and eventual FDA approval of xF liquid biopsy. This pricing power suggests that Tempus's data-enhanced tests command premiums.
The Data & Applications segment, while smaller at $316 million revenue (+31%), is strategically valuable. The Insights licensing business grew 69% in Q4 2025, with net revenue retention of 126%. Total contract value exceeded $1.1 billion, including $300 million in potential opt-ins. This indicates that pharmaceutical customers view Tempus's data as mission-critical, creating a recurring revenue stream that should command a higher valuation multiple than transactional diagnostics revenue.
Margin inflection is a significant financial development. Tempus achieved positive adjusted EBITDA in Q3 2025 for the first time, reaching approximately $65 million in Q4. This milestone validates that the company can achieve profitability while growing. The company is investing in MRD testing, AI applications, and data infrastructure while still generating operating leverage. Gross margin of 62.74% provides room for further improvement as scale increases.
However, GAAP profitability remains a future goal. Net loss was $245 million in 2025, and operating cash flow was negative $218 million. The company has an accumulated deficit of $2.40 billion and $1.30 billion in indebtedness, including $750 million in convertible notes issued in July 2025. This highlights the capital intensity of building both a diagnostics lab network and a data platform. The $1.3 billion cash position and $300 million remaining ATM capacity provide runway, though sustained cash burn remains a key risk.
Outlook, Management Guidance, and Execution Risk
Management's guidance for 2026—$1.59 billion in revenue and approximately $65 million in adjusted EBITDA—implies 25% top-line growth with maintained profitability. This signals confidence that the margin inflection is the beginning of sustained operating leverage. The company explicitly targets 25% annual growth through 2028, prioritizing durability over short-term bursts.
Key assumptions underpinning this outlook include continued ASP improvement from FDA approvals, oncology volume growth remaining in the mid-20% range, and hereditary growth moderating to low-to-mid-20%. Management expects MRD reimbursement by end-2025, though it won't meaningfully impact revenue until 2026. This matters because MRD testing represents a massive market opportunity that Tempus is currently managing carefully due to reimbursement timelines. Once MolDx establishes reimbursement, Tempus could become a significant MRD supplier given its portfolio of naive and informed products across multiple cancer types.
The foundation model timeline is critical. Completion in Q1 2026 will demonstrate whether Tempus can deliver on its promise to build a large-scale oncology AI model. Success would validate the company's AI capabilities and likely drive additional pharma partnerships, while delays could raise questions about execution. The non-exclusive structure provides downside protection, but the AstraZeneca deal's success remains a key catalyst.
Execution risks are evident in management's commentary. While the company is scaling in data and AI, it faces constraints. The sales force is currently limited in MRD efforts due to reimbursement uncertainty. Integration of recent acquisitions must deliver synergies to justify the $810 million spent. And the migration to FDA-approved versions of tests requires navigating complex regulatory pathways. These factors represent potential bottlenecks that could slow growth or increase costs beyond guidance.
Risks and Asymmetries: What Could Break the Thesis
Patent infringement lawsuits from Guardant Health represent an immediate and material risk. Filed in 2024 and 2025, these cases target Tempus's liquid biopsy technology. An adverse ruling could force Tempus to pay royalties, modify its xF assay, or face injunctions that constrain MRD growth. This impacts the $500+ ASP upside management has guided to, as liquid biopsy is a key component. While the company has not disclosed detailed legal strategies, the litigation creates uncertainty that could pressure the stock until resolved.
Reimbursement uncertainty for AI algorithms is both a risk and an opportunity. Management notes that while FDA-approved algorithms for atrial fibrillation are reimbursed at ~$120, most AI diagnostics remain unpaid. If the healthcare system fails to establish broader reimbursement mechanisms, Tempus's Algos business and foundation model investments could generate lower returns. Conversely, successful reimbursement would unlock a high-margin revenue stream not currently in guidance, creating upside asymmetry.
Customer concentration poses a strategic risk. Management's commentary suggests reliance on large pharma partners for the Data & Applications segment. The AstraZeneca/Pathos deal alone represents $200 million over three years. If R&D budgets are cut or partners develop in-house capabilities, Tempus could lose major contracts. The Data segment's 126% net revenue retention and >$1.1 billion TCV are key valuation drivers, making diversification beyond top clients critical for long-term stability.
Supplier concentration creates operational vulnerability. Illumina (ILMN) accounts for 33-39% of total vendor payments from 2023-2025, making Tempus dependent on a single sequencing technology provider. Any supply disruption, price increase, or competitive shift in sequencing technology could impact Tempus's cost structure and gross margins. This dependency represents a hidden operational risk.
Regulatory uncertainty remains a wildcard. While a federal court invalidated the FDA's attempt to regulate laboratory-developed tests (LDTs) in March 2025, future administrations could reinstitute such policies. These factors could increase compliance costs or constrain operational flexibility, impacting the path to sustained profitability.
Competitive Context and Positioning: Why Integration Beats Specialization
Tempus's competitive positioning is best understood through direct comparison. Against Guardant Health, Tempus offers a broader platform. While GH reported $982 million in 2025 revenue (+33%) with 66% gross margins, it remains focused primarily on liquid biopsy. Tempus's 83% growth and integrated data platform provide superior pharma partnership opportunities, though GH's established reimbursement in screening gives it an edge in pure diagnostics. Tempus trades at 5.96x sales versus GH's 11.51x, suggesting a valuation gap.
Versus Natera, which generated $2.3 billion in 2025 revenue (+35.9%) with 64.7% gross margins, Tempus's data moat is the differentiator. NTRA excels in MRD testing but lacks the multimodal data platform that drives Tempus's 126% net revenue retention. Tempus's smaller scale reflects earlier-stage growth, but its 83% growth rate outpaces NTRA's, suggesting potential for multiple expansion as it scales.
Compared to Illumina, the sequencing technology provider, Tempus is a services company with higher growth potential. ILMN's $4.34 billion in 2025 revenue was flat year-over-year, with 68.25% gross margins but slower innovation in AI applications. Tempus's services model requires less capital intensity than ILMN's hardware business, but its dependency on ILMN for sequencers creates a supplier dynamic that could pressure margins if sequencing costs rise.
IQVIA (IQV) represents the data services incumbent, with $16.31 billion in 2025 revenue (+5.9%) and strong profitability. While IQVIA is far larger and more profitable, its 5.9% growth is lower than Tempus's 83%, and its generalist approach lacks Tempus's oncology-specific AI depth. Tempus's challenge is to achieve higher margins while maintaining superior growth, a path that becomes more credible with the recent EBITDA inflection.
Valuation Context: Pricing in Execution, Not Perfection
At $42.37 per share, Tempus trades at a market cap of $7.57 billion and enterprise value of $8.15 billion, representing 5.96x trailing twelve months sales. This positions Tempus at a discount to pure-play diagnostics peers like Guardant Health (11.51x sales) and Natera (11.48x sales), despite higher revenue growth. The discount likely reflects Tempus's recent profitability inflection and higher debt load, but it also suggests potential upside if the company executes on its guidance.
Key valuation metrics must be interpreted through the lens of Tempus's transition phase. The -19.27% profit margin and -16.70% operating margin are improving but still negative, making traditional P/E multiples less applicable. Instead, focus remains on revenue growth quality, margin trajectory, and cash burn. The company's $1.3 billion cash position against $218 million in annual operating cash flow burn implies roughly six years of runway at current burn rates, providing strategic flexibility.
The enterprise value-to-revenue multiple of 6.41x compares favorably to high-growth healthcare technology peers, particularly when factoring in the >$1.1 billion total contract value that provides revenue visibility. The 62.74% gross margin reflects the blended nature of diagnostics and data services. As the higher-margin Data segment grows and diagnostics scales, gross margin expansion should support multiple expansion.
The valuation implies that the market is pricing in successful execution of the 25% growth target through 2028 and modest margin improvement, but not a full realization of the AI reimbursement opportunity or MRD market capture. This creates asymmetry: downside is supported by the tangible diagnostics business and contract backlog, while upside could be substantial if AI algorithms achieve reimbursement and the foundation model delivers breakthrough insights.
Conclusion: The Crossroads of Data, Diagnostics, and AI
Tempus AI stands at a critical inflection point where a decade of investment in building an integrated diagnostics and data platform is beginning to generate both profitable growth and defensible competitive moats. The Q3 2025 achievement of positive adjusted EBITDA validates that the business model can scale efficiently, while the 83% revenue growth and >$1.1 billion contract value demonstrate that customer demand remains robust. The central thesis hinges on whether Tempus can maintain this trajectory while capturing the untapped value of AI reimbursement.
The key variables that will determine success are threefold. First, resolution of the Guardant Health litigation will clarify the path for liquid biopsy and MRD expansion, impacting the $500+ ASP upside management has outlined. Second, timing of AI algorithm reimbursement from CMS and commercial payers will determine whether the Algos business becomes a high-margin revenue driver. Third, execution on integrating Ambry, Paige, and Deep 6 while scaling the sales force will test whether Tempus can maintain its growth rate without margin degradation.
If Tempus executes successfully, the stock's 5.96x sales multiple appears conservative relative to peers, particularly given the dual revenue engines of diagnostics and data. The company's unique position—combining the testing volumes of a diagnostics leader with the data assets of a healthcare AI platform—creates a flywheel that becomes more valuable with scale. For investors willing to accept the risks of patent litigation and reimbursement uncertainty, Tempus offers a combination of near-term margin inflection and long-term AI-driven upside.
